These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 25323804)

  • 1. Pharmacokinetic interactions between simvastatin and setipiprant, a CRTH2 antagonist.
    Gehin M; Sidharta PN; Gnerre C; Treiber A; Halabi A; Dingemanse J
    Eur J Clin Pharmacol; 2015 Jan; 71(1):15-23. PubMed ID: 25323804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Setipiprant, a selective oral antagonist of human CRTH2: relative bioavailability of a capsule and a tablet formulation in healthy female and male subjects.
    Baldoni D; Mackie A; Gutierrez M; Theodor R; Dingemanse J
    Clin Ther; 2013 Nov; 35(11):1842-8. PubMed ID: 24095247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single- and multiple-dose tolerability and pharmacokinetics of the CRTH2 antagonist setipiprant in healthy male subjects.
    Sidharta PN; Diamant Z; Dingemanse J
    Fundam Clin Pharmacol; 2014 Dec; 28(6):690-9. PubMed ID: 24734908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Setipiprant, a selective CRTH2 antagonist, reduces allergen-induced airway responses in allergic asthmatics.
    Diamant Z; Sidharta PN; Singh D; O'Connor BJ; Zuiker R; Leaker BR; Silkey M; Dingemanse J
    Clin Exp Allergy; 2014 Aug; 44(8):1044-52. PubMed ID: 24964348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disposition and metabolism of setipiprant, a selective oral CRTH2 antagonist, in humans.
    Hoch M; Wank J; Kluge I; Wagner-Redeker W; Dingemanse J
    Drugs R D; 2013 Dec; 13(4):253-69. PubMed ID: 24214422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic interactions of almorexant with midazolam and simvastatin, two CYP3A4 model substrates, in healthy male subjects.
    Hoch M; Hoever P; Alessi F; Theodor R; Dingemanse J
    Eur J Clin Pharmacol; 2013 Mar; 69(3):523-32. PubMed ID: 22990330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Almorexant effects on CYP3A4 activity studied by its simultaneous and time-separated administration with simvastatin and atorvastatin.
    Hoch M; Hoever P; Theodor R; Dingemanse J
    Eur J Clin Pharmacol; 2013 Jun; 69(6):1235-45. PubMed ID: 23334403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of 2-(2-(1-naphthoyl)-8-fluoro-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)acetic acid (setipiprant/ACT-129968), a potent, selective, and orally bioavailable chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2) antagonist.
    Fretz H; Valdenaire A; Pothier J; Hilpert K; Gnerre C; Peter O; Leroy X; Riederer MA
    J Med Chem; 2013 Jun; 56(12):4899-911. PubMed ID: 23721423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of repeated administration of eslicarbazepine acetate on the pharmacokinetics of simvastatin in healthy subjects.
    Falcão A; Pinto R; Nunes T; Soares-da-Silva P
    Epilepsy Res; 2013 Sep; 106(1-2):244-9. PubMed ID: 23726291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic/Pharmacodynamic Modelling of Receptor Internalization with CRTH2 Antagonists to Optimize Dose Selection.
    Krause A; Zisowsky J; Strasser DS; Gehin M; Sidharta PN; Groenen PMA; Dingemanse J
    Clin Pharmacokinet; 2016 Jul; 55(7):813-821. PubMed ID: 26692193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, and simvastatin following co-administration in healthy volunteers.
    Macha S; Lang B; Pinnetti S; Broedl UC
    Int J Clin Pharmacol Ther; 2014 Nov; 52(11):973-80. PubMed ID: 25161155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disease-Drug Interaction of Sarilumab and Simvastatin in Patients with Rheumatoid Arthritis.
    Lee EB; Daskalakis N; Xu C; Paccaly A; Miller B; Fleischmann R; Bodrug I; Kivitz A
    Clin Pharmacokinet; 2017 Jun; 56(6):607-615. PubMed ID: 27722854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Cilostazol on the Pharmacokinetics of Simvastatin in Healthy Subjects.
    Kim JR; Jung JA; Kim S; Huh W; Ghim JL; Shin JG; Ko JW
    Biomed Res Int; 2019; 2019():1365180. PubMed ID: 30729119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, in patients with moderate hepatic impairment.
    Wang YH; Liu F; Luk JA; Nirula A; Johnson-Levonas AO; Lasseter KC; Marbury TC; Lunde NM; Wagner JA; Lai E
    J Clin Pharmacol; 2011 Mar; 51(3):406-12. PubMed ID: 20484612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of drugs interacting with CYP3A4 on the pharmacokinetics, pharmacodynamics, and safety of the prandial glucose regulator repaglinide.
    Hatorp V; Hansen KT; Thomsen MS
    J Clin Pharmacol; 2003 Jun; 43(6):649-60. PubMed ID: 12817528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of multiple doses of clarithromycin on the pharmacokinetics of laropiprant in healthy subjects.
    Wang YH; Schwartz JI; Luo WL; Jumes P; Desai R; Wenning LA; Wagner JA; Lai E
    Cardiovasc Ther; 2011 Apr; 29(2):140-5. PubMed ID: 20337634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigation of combined CYP3A4 inductive/inhibitory properties by studying statin interactions: a model study with the renin inhibitor ACT-178882.
    Dingemanse J; Nicolas LB; van Bortel L
    Eur J Clin Pharmacol; 2014 Jun; 70(6):675-84. PubMed ID: 24728182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of linagliptin (BI 1356) on the steady-state pharmacokinetics of simvastatin.
    Graefe-Mody U; Huettner S; Stähle H; Ring A; Dugi KA
    Int J Clin Pharmacol Ther; 2010 Jun; 48(6):367-74. PubMed ID: 20497745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of laropiprant, a selective prostaglandin D(2) receptor 1 antagonist, on the pharmacokinetics of rosiglitazone.
    Schwartz JI; Stroh M; Gao B; Liu F; Rosko K; Zajic S; Meehan AJ; Ruckle J; Lai E; Wagner JA
    Cardiovasc Ther; 2009; 27(4):239-45. PubMed ID: 19903187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, on the steady-state pharmacokinetics of digoxin in healthy adult subjects.
    Liu F; Vessey L; Wenning L; Connolly S; Buckland M; Johnson-Levonas AO; Denker A; Wagner JA; Lai E
    J Clin Pharmacol; 2010 Jul; 50(7):823-8. PubMed ID: 20197486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.